PILLS Act
Why China-relevant: Credit 'shall not be allowed to any taxpayer which... was a foreign entity of concern (as defined in section 9901(8) of the... NDAA for FY2021 (15 U.S.C. 4651))' -- FEOC mechanism scoping China; no direct China naming.
Path to becoming law
- Introduced
- Passed committee next step
- Passed House
- Passed Senate
- Sent to President
- Became law
done next step still ahead
Legislative timeline — dated actions so far
- Filed
1% to become law · 5% to clear committee
- + Sponsored by a member of the majority party
- + 2 cosponsors
- + Has an identical companion bill in the other chamber
- − Cosponsors are nearly all one party
Legislative likelihood — a tracking indicator, not investment advice.
Signals — secondary, directional
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
Onshoring tax credits for generics/biosimilars that exclude FEOC (China-linked) producers disadvantage China-based pharma supply chains.
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |